Zou et al. Phase 2 RCT Vunakizumab, humanized IL17A in PsA. 12 week study. ACR responses shown in figure, looks similar to existing IL17As. @RheumNow #ACR24 Abstr#2581 https://t.co/Td5xlMYrAd https://t.co/Rl4gkmDFOR

• Vunakizumab in Patients with Active Psoriatic Arthritis: A Multicenter, Randomi…
• https://x.com/RichardPAConway/status/1858572630426874065/photo/1

A#2363 Deodhar Bimekizumab fast time to work: BE MOBILE 1 and 2 - rapid treatment responses with separation from PBO as early as 1-2 weeks after single dose. @RheumNow #ACR24 https://t.co/T81Lzyoy7m

• https://x.com/ericdeinmd/status/1858556716075339953/photo/1

Xia et al. Upadacitinib in refractory Behcets. Open label, 8 patients. Follow-up 4-14 months. Lower disease activity 2.5 vs 1.5. Lower pred, 11.9 vs 8.1. @RheumNow #ACR24 Abstr#2515 https://t.co/ZXsJkNRlTm https://t.co/S8LhpqZ8X3

• Upadacitinib for Refractory Behçet’s Syndrome: A Multi-center, Prospective, Ope…
• https://x.com/RichardPAConway/status/1858557782405833156/photo/1

In the horizon for Knee #OA pain management - XG005 - non opioid inhibiting inflammatory and neuropathic signals via the COX enzymes and the calcium subunit. Phase 2b , placebo control, double blind study Abst #L08 #ACR24 @RheumNow https://t.co/j4qkj1Xvbr

• https://x.com/bella_mehta/status/1858558034366304734/photo/1

US biosimilar exp Interchangeable biosimilar - can substitute for reference product wo consulting MD Primary endpt: pharmacokinetic data 61 approved biosimilars @RheumKay: “pts should share in financial benefits” Currently 5-87% discount #PBMReform @ACRheumDC @RheumNow #ACR24 https://t.co/RqwbZalZko

• https://x.com/ericdeinmd/status/1858547083017363622/photo/1
• https://x.com/ericdeinmd/status/1858547083017363622/photo/1
• https://x.com/ericdeinmd/status/1858547083017363622/photo/1

Abstract 1842: Off the shelf CAR T therapy No lymphodepletion needed, delivering robust, targeted CD19+ B cell elimination in multiple in vitro assays @RheumNow #ACR24

If you’re starting with DMARD (according to ACR/VF guidelines) tx in TAK - MTX and AZA are probably equivalent options… MMF not so much @RheumNow #ACR24 https://t.co/jn52ujtspo

• https://x.com/Dr_Brian_MD/status/1858537546902335997/photo/1

Early observational data suggesting JAK inhibitors can play a role in TAK tx We have seen this with UPA in GCA this conference… time for SELECT-TAK ! @RheumNow #ACR24 https://t.co/B2Wa8sOFTp

• https://x.com/Dr_Brian_MD/status/1858538311314235670/photo/1

#ACR24 - Featured Industry Presentations Many of the great presentations for this meeting come from industry sponsored clinical trials and reports. Often these become the pivotal studies for regulatory approval and the annual congresses are their first look.… https://t.co/I6LMQ5xMUx https://t.co/UzTeqWUSdo

Gottenberg et al. A positive RCT in pSS! DAHLIAS study. Phase 2. 163 patients. Nipocalimab, anti-neonatal Fc receptor (FcRn) mAb. @RheumNow #ACR24 Abstr#2527 https://t.co/M7li4ZoKeY https://t.co/gV9MGnswdR

• Efficacy and Safety of Nipocalimab, an Anti-FcRn Monoclonal Antibody, in Primar…
• https://x.com/RichardPAConway/status/1858513994107297997/photo/1

Nipocalimab, an anti-neonatal Fc receptor (FcRn) mAb, reduces circulating IgG including specific autoantibodies (AAb), by selectively blocking IgG–FcRn interactions. DAHLIAS, the first study of a FcRn blocker in SjD, showed that nipocalimab led to significant improvement vs PBO… https://t.co/zl1tEsEMAj https://t.co/qrkOD2Ccc3

• https://x.com/i/web/status/1858514245820051729
• https://x.com/synovialjoints/status/1858514245820051729/photo/1

A#2527 DAHLIAS, P2 Nipocalimab: Anti-FcRn Ab in Ro+ SjD IV 5 or 15 mg/kg Prim Endpt: 15 mg/kg has ClinESSDAI at w24 -6.4 v -3.7 PBO p=0.002 Improv dryness, fatigue, pain Better unstim salivary flow Best response in higher Ab titer pts Safety data good #ACRBest #ACR24 @RheumNow https://t.co/O7zahPul66

• https://x.com/ericdeinmd/status/1858514479035650062/photo/1
• https://x.com/ericdeinmd/status/1858514479035650062/photo/1
• https://x.com/ericdeinmd/status/1858514479035650062/photo/1

Phase 2 DAHLIA study in Sjogrens Anti-neonatal Fc receptor an “nipocalimab” w/remarkably encouraging results clinESSDAI significantly better at wk24, notably met QOL domains as well Finally getting good news in SjS! #ACR24 @RheumNow #ACRbest Abst#2527 https://t.co/e3uQmqJZ1o

• https://x.com/EBRheum/status/1858514973355286783/photo/1
• https://x.com/EBRheum/status/1858514973355286783/photo/1
• https://x.com/EBRheum/status/1858514973355286783/photo/1
• https://x.com/EBRheum/status/1858514973355286783/photo/1

I have no doubt many of our RA patients will take GLP-1 agonists in the future. Here's some data @UCLA showing significant differences in not just body weight and HbA1c, but pain. Will be fascinating to see what it does for grumbling disease activity! #ACR24 ABST2259 @RheumNow https://t.co/HdOPACEo3A

• https://x.com/drdavidliew/status/1858491323172671539/photo/1